DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for inflammatory bowel disease 13 — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleInflammatory bowel disease 13 maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for inflammatory bowel disease 13 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ATP binding cassette subfamily B member 1 (ABCB1) — ABCB1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet r0zdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8Y6H · 2.49 Å · ligand elacridar (R0Z). Experimental structure, not a prediction.
What the evidence adds up to
The abstracts provided do not test any drug for repurposing in inflammatory bowel disease. One 2018 Danish cohort followed 213 Crohn’s disease and 300 ulcerative colitis patients for ten years and recorded real-world treatment escalation. Younger age at diagnosis was associated with escalation to immunosuppressants or biologics in Crohn’s disease (odds ratio 0.7 for age 17–40, 0.5 for age over 40, versus age under 17). In ulcerative colitis, former smoking (odds ratio 1.3) and disease extent at diagnosis (odds ratio 1.4 for left-sided and for extensive colitis versus proctitis) were associated with escalation. After the first few years, treatment levels stabilised in both groups. No response rates, survival figures, or drug-specific outcomes are reported.
A 2022 pipeline review notes that anti-TNF therapies improve clinical outcomes but primary failure and secondary loss of response are common, and side effects limit long-term use. New targeted agents are in development, but the review states that more data are needed to understand their best positioning in treatment pathways and their longer-term safety. No concrete efficacy numbers from any trial are given.
Two reviews from 2014 and one from 2019 discuss patient-reported outcome measures and de-escalation of biological therapy, respectively. The 2019 review states that patients often request to discontinue biological drugs because of cost and the risk of malignancy, but it provides no trial data on relapse rates after stopping or on success of retreatment. The PROMs reviews note methodological challenges in development and validation but contain no drug results.
What is missing: no randomised controlled trial of any repurposed drug is presented; no biomarker or stratification strategy is tested; no funding for such a trial is mentioned. The cohort study describes escalation patterns but does not test a specific intervention.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Immunopharmacology and Immunotoxicology · 2018 · 58 citations
Review of<i>Saccharomyces boulardii</i>as a treatment option in IBD
AbstractCONTEXT: Review of the yeast Saccharomyces boulardii as a treatment option for the inflammatory bowel diseases (IBD) ulcerative colitis and Crohn's disease. OBJECTIVE: IBD is caused by an inappropriate immune response to gut microbiota. Treatment options could therefore be prebiotics, probiotics, antibiotics and/or fecal transplant. In this review, we have looked at the evidence for the yeast S. boulardii as a treatment option. MATERIAL AND METHODS: Searches in PubMed and the Cochrane Library with the MeSH words 'Saccharomyces boulardii AND IBD', 'Saccharomyces boulardii AND Inflammatory Bowel Disease', 'Saccharomyces boulardii AND ulcerative colitis' and 'Saccharomyces boulardii AND Crohn's disease' gave total a total of 80 articles. After exclusions because of irrelevance, articles in other languages and some articles that were not available, 16 articles were included in this review. RESULTS: Three of the clinical trials showed a positive effect of S. boulardii in IBD patients (two Crohn's disease, one ulcerative colitis), while there was one trial that didn't prove any effect (Crohn's disease). Included Animal trials and cell assays describes different anti-inflammatory mechanisms of S. boulardii supporting a possible effect when treating IBD patients. DISCUSSION: The number of studies of S. boulardii as treatment for IBD is limited. Furthermore, the existing trials have small populations and short duration. CONCLUSION: We do not have enough evidence to prove the effect of S. boulardii in IBD. Saccharomyces boulardii is, however, a plausible treatment option in the future, but more placebo-controlled clinical studies on both patients with ulcerative colitis and Crohn's disease are needed.
Canadian Journal of Gastroenterology and Hepatology · 2014 · 44 citations · open access
Patient-Reported Outcome Measures in Inflammatory Bowel Disease
AbstractPatient-reported outcome measures (PROMs) are increasingly used in both research and clinical health settings. With the recent development of United States Food and Drug Administration guidance on PROMs, more attention is being devoted to their role and importance in health care. Several methodological challenges in the development, validation and implementation of PROMs must be resolved to ensure their appropriate utilization and interpretation. The present review discusses recent developments and updates in PROMs, with specific focus on the area of inflammatory bowel disease.
Frontline Gastroenterology · 2022 · 12 citations · open access
IBD therapeutics: what is in the pipeline?
AbstractInflammatory bowel disease (IBD) is an idiopathic long-term relapsing and remitting disorder including ulcerative colitis and Crohn's disease. The aim of therapy is to induce and maintain remission. Anti-TNF therapies dramatically improved clinical outcomes but primary failure or secondary loss is a common problem as well as potential side effects potentially limiting efficacy and long-term use. The advent of new targeted agents with the potential for greater safety is welcomed in IBD and offers the potential for different agents as the disease becomes refractory or even combination therapies to maximise effectiveness without compromising safety in the future. More data are required to understand the best positioning in pathways and longer-term safety effects.
South African Medical Journal · 2019 · 6 citations · open access
De-escalation of biological therapy in inflammatory bowel disease: Benefits and risks
AbstractThe treatment of inflammatory bowel disease (IBD) is often challenging. It has a vexing and waning course with frequent relapses, despite adequate maintenance therapy. Biological agents have been available for the treatment of IBD for the last two decades, with impressive results. However, these drugs are costly and often have significant side-effects. Therefore, the benefit of aggressive treatment must be carefully balanced against the risk of serious adverse events. Despite good clinical outcomes, patients often request to discontinue the drugs because of cost and detrimental effects, especially the risk of malignancy. This review focuses on the benefits of biological treatment, strategies to de-escalate therapy, risk of relapse when these agents are discontinued and success with retreatment with the same or a similar biological agent.
Greater South Information System · 2014 · 0 citations · open access
Patient-Reported Outcome Measures in Inflammatory Bowel Disease
AbstractPatient-reported outcome measures (PROMs) are increasingly used in both research and clinical health settings. With the recent development of United States Food and Drug Administration guidance on PROMs, more attention is being devoted to their role and importance in health care. Several methodological challenges in the development, validation and implementation of PROMs must be resolved to ensure their appropriate utilization and interpretation. The present review discusses recent developments and updates in PROMs, with specific focus on the area of inflammatory bowel disease.
Greater South Information System · 2014 · 0 citations · open access
Patient-Reported Outcome Measures in Inflammatory Bowel Disease
AbstractPatient-reported outcome measures (PROMs) are increasingly used in both research and clinical health settings. With the recent development of United States Food and Drug Administration guidance on PROMs, more attention is being devoted to their role and importance in health care. Several methodological challenges in the development, validation and implementation of PROMs must be resolved to ensure their appropriate utilization and interpretation. The present review discusses recent developments and updates in PROMs, with specific focus on the area of inflammatory bowel disease.
Journal of Crohn s and Colitis · 2018 · 0 citations · open access
P786 The use and escalation of treatments in patients with inflammatory bowel disease; a 10 years follow-up of a Danish population-based inception cohort
AbstractThe long-term treatment strategies and change between medications in Inflammatory bowel disease (IBD) in the age of biologics has not been well described. We aimed to characterise the treatment strategies in IBD in a well-defined population-based inception cohort of Crohn's disease (CD) and ulcerative colitis (UC) patients after 10 years of follow-up. All patients (n = 513) diagnosed with CD, UC or IBD unclassified between January 1, 2003 and December 31, 2004 in a well-defined area were included. Clinical data regarding treatment and outcome were recorded and patient records linked with four national registries to ensure complete data capture and follow-up. Treatments were grouped into four treatment levels (TL): (1) 5-aminosalicylates (5-ASA) ± topical steroids, (2) oral steroids ± 5-ASA or topical steroids, (3) immunosuppressant (azathioprine or 6-mercaptopurine ± steroids and/or 5-ASA), (4) biologics (infliximab or adalimumab in combination with any of the above). Disease classification was made according to the Montreal classification. In a linear regression model, gender, age class, diagnostic delay, smoking behaviour, disease behaviour, location, and extent at diagnosis was used as independent variables. A total of 213 CD and 300 UC patients were followed. TL over time is shown in Figure 1 and 2. Characteristics of patients’ TL are shown in Table 1. In CD, only younger age at diagnosis was associated with the risk of escalating to TL 3 or 4 (OR (CI 95); A2: 0.7 (0.5, 0.98); A3: 0.5 (0.4,0.8) [ref: A1]). In UC patients, former smoking (OR (CI95); 1.3 (1.0–1.6) [ref: never smoker]), and extent at diagnosis was significantly associated with the risk of escalating to TL 3 or 4 (OR (CI95); E2: 1.4 (1.2,1.8), p < 0.001; E3: 1.4 (1.1,1.7) [ref: E1]). After the first initial years after diagnosis, stability occurs regarding treatment levels of both CD and UC patients. Escalation to immunomodulators and biologics was more frequently necessary in CD, even after the initial years, compared with UC patients. Crohn’s disease patients’ treatment level throughout 10 years of follow-up ulcerative colitis patients’ treatment level throughout 10 years of follow-up Characteristics of Crohn’s disease and Ulcerative colitis patients’ treatment level after 10 years of follow-up
Journal of Exploratory Research in Pharmacology · 2017 · 0 citations · open access
The Role of Infliximab Biosimilar CT-P13 in Inflammatory Bowel Disease
AbstractThe advent of targeted biologic therapies for debilitating disorders such as Crohn’s disease (CD) and Ulcerative Colitis (UC) has changed management and significantly improved outcomes. However, biologic agents are expensive, and the introduction of biosimilar medications for the treatment of inflammatory bowel diseases presents a lower-cost alternative. In this review, the mechanism of action, pharmacokinetics, efficacy and adverse effects associated with biosimilar CT-P13 in the treatment of inflammatory bowel disease are discussed.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
